Phase I - II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. - Reusser ,P.; Gambertoglio ,J.G.; Lilleby ,K.; Meyers ,J.D. (J Infect Dis, 1992)